gemcitabine, oxaliplatin

TERMINATED · PHASE2 · Carcinoma, Transitional Cell

Unknown stopping reason

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.